FDA approves Alembic’s Paroxetine ER tablets
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets are indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg
Prolia is a prescription medicine used to treat osteoporosis in women
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Relonchem receives marketing authorization for Moxonidine tablets
Subscribe To Our Newsletter & Stay Updated